skingenix
About Us
Skingenix, Inc., a leader in dermal regeneration technologies specializing in the research and development of botanical drug products, is located at Arcadia, California. As an innovative and mission-driven company, Skingenix pursues a standard of excellence in the regenerative medical industry with an emphasis on developing organ in situ regenerative products for improving human health and quality of life. Skingenix’s core product, MEBO® Wound Ointment (MEBO) is a proprietary formulation of natural botanical products for patients with burn injuries and other cutaneous wounds. The company has an active Phase II Investigational New Drug (IND) application with the Food and Drug Administration (FDA) in the United States.

MEBO International Group, a Beijing-headquartered, multinational company being highly recognized in the regenerative medical society, is the drug product distributor. Since its first marketing approval in China in 1988, MEBO has been privileged as China’s standard of care for burns. MEBO has been used to treat burns, chronic wounds and ulcers in twenty-four countries with more than four million estimated patient uses.

The non-clinical pharmacological studies on MEBO, are likely to be important for the development of novel and optimized strategies for wound healing. Additionally, controlled clinical trials conducted independently also from Skingenix, Inc. are considered to evaluate the safety and efficacy of MEBO in the treatment of burns, chronic wounds, ulcers and scars.

Our Vision
Worldwide recognition and application of organ in situ regeneration in pursuit for the realization of the best quality of health management, longer lifespan, and a secured future. The Company is dedicated to achieve this vision by combining its earned proprietary technologies and formulation of essential botanical products for an excellent health.
 
Our Mission
To provide cutting-edge regenerative technologies on preventing, alleviating and curing human diseases with continuing development of botanical drug products that are safe, effective and nature regenerative in situ. Skingenix’s ultimate goals are to improve the quality of human life through the harmony of nature and science, benefit humanity, and deliver outstanding botanical drug products in the market.
 
Copyright © 2009-2010 SKINGENIXWEB.COM. All Rights Reserved
The Skingenix, Inc. website has been designed for the audience worldwide. This website contains information about products which may or may not be available in different countries. In addition, the official approval or market clearance for indications of use may also differ per each country. Please consult individual country sites for approved uses and any applicable restrictions.The research data disclosed in this website is wholly for the purpose of scientific information exchange and is not intended for marketing or promotional uses.

Please note that Skingenix's drug product MEBO® Wound Ointment has not been approved by the Food and Drug Administration for any indication of use in the United States. It is currently under the status of Investigational New Drug (Phase II) for patients with burn injuries, venous stasis ulcers and diabetic foot ulcers.